Drug intelligence / Profile preview

raltegravir

Development stage: Approved
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

Raltegravir is an antiretroviral medication that belongs to the HIV integrase inhibitor class. It works by inhibiting HIV integrase, preventing the viral genome from being incorporated into the human genome, thus decreasing the amount of HIV in the blood. Although raltegravir does not cure HIV, it may decrease the chance of developing AIDS and HIV-related illnesses such as serious infections or cancer. Raltegravir was the first integrase inhibitor approved by the FDA on October 12, 2007. It is primarily metabolized by glucuronidation via UGT1A1 and is used in combination with other antiretroviral medications to treat HIV infection. It was developed and is manufactured by Merck & Co.

Brand names: IsentressIsentress HD
Other names: RALraltegravir potassium

Targets

Integrase allosteric pocket (HIV)

Beyond the preview

Go deeper on raltegravir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on raltegravir.

Explore the full profile